文献速递眼底病与葡萄膜炎

HAWK与HARRIER研究中布西珠单抗与阿柏西普治疗患者视网膜下高反射物质的对比评估

Comparative assessment of subretinal hyper-reflective material in patients treated with brolucizumab versus aflibercept in HAWK and HARRIER.
PubMed 文献 · Br J Ophthalmol · 2024-05-21

对III期HAWK和HARRIER研究的事后分析,比较布西珠单抗6 mg与阿柏西普2 mg治疗96周内视网膜下高反射物质(SHRM)厚度的降低程度。布西珠单抗组SHRM厚度自基线降低百分比在数值上高于阿柏西普组(第96周:54.4% vs 47.6%);第12周SHRM厚度较低及SHRM厚度变异性较低的眼睛视力获益更大。数据提示负荷后SHRM厚度及随时间变化的SHRM厚度变异性是新生血管性年龄相关性黄斑变性(nAMD)视力结局的生物标志物。

要点

  • 布西珠单抗组SHRM厚度自基线降低百分比在数值上高于阿柏西普组(第96周:54.4% vs 47.6%)。
  • 第12周SHRM厚度<200 µm的眼睛第96周平均BCVA自基线增益为+6.47个ETDRS字母,≥200 µm者为+3.10个字母。
  • 第12周至第96周SHRM厚度变异性<12 µm的眼睛第96周平均BCVA自基线增益为+7.42个字母,>71 µm者为-2.95个字母。

核心结论

  • 在HAWK和HARRIER研究中,布西珠单抗较阿柏西普观察到更大的最大SHRM厚度自基线降低。
  • 数据提示负荷后SHRM厚度及随时间变化的SHRM厚度变异性是nAMD患者视力结局的生物标志物。

研究设计与样本

  • III期HAWK和HARRIER研究的事后分析,比较布西珠单抗6 mg与阿柏西普2 mg治疗。
  • 分析布西珠单抗组(n=700)与阿柏西普组(n=696)共96周内黄斑区最大SHRM厚度的OCT图像。
  • 汇总的治疗不可知分析评估第12周SHRM厚度及SHRM厚度变异性对第96周BCVA的影响。

主要发现

  • 所有患者中布西珠单抗组SHRM厚度自基线降低百分比在数值上高于阿柏西普组(第96周:54.4% vs 47.6%)。
  • 第16周有疾病活动的匹配亚组中布西珠单抗组SHRM厚度自基线降低百分比在数值上高于阿柏西普组(第96周:51.6% vs 33.8%)。
  • 第12周SHRM厚度<200 µm的眼睛第96周平均BCVA自基线增益为+6.47个ETDRS字母,≥200 µm者为+3.10个字母。
  • 第12周至第96周SHRM厚度变异性<12 µm的眼睛第96周平均BCVA自基线增益为+7.42个字母,>71 µm者为-2.95个字母。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Post hoc analysis of the phase III HAWK and HARRIER studies to compare the reductions in subretinal hyper-reflective material (SHRM) thickness following brolucizumab 6 mg or aflibercept 2 mg treatment and to assess SHRM thickness and thickness variability as a potential biomarker of visual outcomes in patients with neovascular age-related macular degeneration (nAMD). METHODS: Optical coherence tomography images from the brolucizumab (n=700) and aflibercept (n=696) arms were analysed for the maximum SHRM thickness across the macula over 96 weeks. In a pooled treatment-agnostic analysis, the effect of week 12 SHRM thickness and SHRM thickness variability on best-corrected visual acuity (BCVA) through week 96 were also assessed. RESULTS: Brolucizumab was associated with numerically higher percentage reductions from baseline in SHRM thickness versus aflibercept in all patients (week 96: 54.4% vs 47.6%, respectively) and also in the matched subgroups with disease activity at week 16 (week 96: 51.6% vs 33.8%, respectively). In eyes with lower SHRM measurements at week 12, mean BCVA gains from baseline were higher at week 96 (<200 µm, +6.47 Early Treatment Diabetic Retinopathy Study letters; ≥200 µm, +3.10 letters). Eyes with the lowest SHRM thickness variability from week 12 to week 96 showed the greatest mean BCVA gains from baseline (week 96: <12 µm, +7.42 letters; >71 µm, -2.95 letters). CONCLUSIONS: In HAWK and HARRIER, greater reductions in maximum SHRM thickness from baseline were observed with brolucizumab compared with aflibercept. Furthermore, the data suggest that SHRM thickness postloading and SHRM thickness variability over time are biomarkers for visual outcomes in patients with nAMD.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Sadda S, Sarraf D, Khanani AM, et al. Comparative assessment of subretinal hyper-reflective material in patients treated with brolucizumab versus aflibercept in HAWK and HARRIER. Br J Ophthalmol. 2024. PMID: 37669850. doi:10.1136/bjo-2023-323577

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。